EGFR and glioblastoma: In fact, this and previous studies showed that TAT-Cx43266–283 decreased cell viability in primary GSCs and GBM explants in most patients analyzed.35 Interestingly, although EGFR and EGFRvIII protein levels and activity match with TAT-Cx43266–283 effect, our results suggest that EGFR amplification or EGFRvIII version determined by genetic testing, commonly available in the clinical diagnostic, are sufficient to predict TAT-Cx43266–283 response.